Journal article icon

Journal article

A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study

Abstract:
BACKGROUND: A detailed understanding of the pathological processes involved in genetic frontotemporal dementia is critical in order to provide the patients with an optimal future treatment. Protein levels in CSF have the potential to reflect different pathophysiological processes in the brain. We aimed to identify and evaluate panels of CSF proteins with potential to separate symptomatic individuals from individuals without clinical symptoms (unaffected), as well as presymptomatic individuals from mutation non-carriers. METHODS: A multiplexed antibody-based suspension bead array was used to analyse levels of 111 proteins in CSF samples from 221 individuals from families with genetic frontotemporal dementia. The data was explored using LASSO and Random forest. RESULTS: When comparing affected individuals with unaffected individuals, 14 proteins were identified as potentially important for the separation. Among these, four were identified as most important, namely neurofilament medium polypeptide (NEFM), neuronal pentraxin 2 (NPTX2), neurosecretory protein VGF (VGF) and aquaporin 4 (AQP4). The combined profile of these four proteins successfully separated the two groups, with higher levels of NEFM and AQP4 and lower levels of NPTX2 in affected compared to unaffected individuals. VGF contributed to the models, but the levels were not significantly lower in affected individuals. Next, when comparing presymptomatic GRN and C9orf72 mutation carriers in proximity to symptom onset with mutation non-carriers, six proteins were identified with a potential to contribute to a separation, including progranulin (GRN). CONCLUSION: In conclusion, we have identified several proteins with the combined potential to separate affected individuals from unaffected individuals, as well as proteins with potential to contribute to the separation between presymptomatic individuals and mutation non-carriers. Further studies are needed to continue the investigation of these proteins and their potential association to the pathophysiological mechanisms in genetic FTD.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s13024-021-00499-4
Publication website:
https://pure.eur.nl/ws/files/53299535/s13024_021_00499_4.pdf

Authors

More by this author
Role:
Author
ORCID:
0000-0003-0635-6377
More by this author
Role:
Author
ORCID:
0000-0002-3908-6476


More from this funder
Funder identifier:
10.13039/501100004359
Grant:
529-2014-7504
More from this funder
Funder identifier:
10.13039/501100003792
More from this funder
Funder identifier:
10.13039/501100005701
More from this funder
Funder identifier:
10.13039/501100004270


Publisher:
BioMed Central
Journal:
Molecular Neurodegeneration More from this journal
Volume:
16
Issue:
1
Pages:
79-79
Article number:
79
Publication date:
2021-11-27
DOI:
EISSN:
1750-1326
ISSN:
1750-1326


Language:
English
Keywords:
Pubs id:
1251076
Local pid:
pubs:1251076
Source identifiers:
W3215312374
Deposit date:
2026-04-10
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP